Onabotulinum A injection belongs to a class of medications called neurotoxins. If you are 65 or older and you will receive it. When onabotulinumtoxinA is injected into a muscle, it blocks nerve signals that cause muscle contraction and uncontrollable movements. When onabotulinumtoxinA is injected into a sweat gland, it decreases the gland's activity to reduce sweating.
When OnabotulinumtoxinA is injected into the bladder, it decreases bladder contractions and blocks signals that tell the nervous system that the bladder is full. Both Botox and Dysport are popular injectable treatments that fall into the category of neurotoxins. These neurotoxins are derived from botulinum toxin type A, also known as onabotulinumtoxinA. They work by blocking the release of a neurotransmitter called acetylcholine, which is responsible for muscle contraction.
By blocking the release of acetylcholine, muscles relax. This muscle relaxation reduces the appearance of fine lines and wrinkles. Although both products work in a similar way, they have some differences in formulation and characteristics. BOTOX falls into the category of cosmetic injectables known as neurotoxins or neuromodulators.
When injected into facial muscles, BOTOX interrupts signals from the central nervous system, causing them to contract. The product temporarily paralyzes these muscles, smoothes dynamic wrinkles and causes the muscles to relax. The smoothing effect not only makes you look younger, but it prevents the movement of these muscles and prevents new lines from forming. However, BOTOX may not be the right neurotoxin for everyone, which is why we also offer Xeomin and Dysport.
Botox (OnabotulinumtoxinA) is an injectable neurotoxin used to treat chronic migraines, limb spasticity, axillary hyperhidrosis, cervical dystonia, strabismus, and blepharospasm. Physicians who administer BOTOX must understand the relevant neuromuscular and structural anatomy of the affected area and any alteration in the anatomy due to previous surgical procedures or diseases, especially when injected near the lungs. A precise injection technique, based on knowledge of nerve signaling and facial muscle anatomy, is key to achieving the desired results with Xeomin and Botox. The safety and efficacy of BOTOX for treating detrusor hyperactivity associated with a neurological condition have been established in pediatric patients aged 5 years or older who cannot tolerate anticholinergic medications or who do not respond adequately to them.
Two hundred and thirty-one patients were enrolled in a double-blind, placebo-controlled study (the study received 300 to 400 units of BOTOX) and compared to 233 patients who received placebo. The most commonly reported adverse reactions (3 to 10% of adult patients) after BOTOX injection in double-blind studies included pain and bleeding at the injection site, non-axillary sweating, infection, pharyngitis, flu-like syndrome, headache, fever, neck or back pain, pruritus and anxiety. In patients with overactive bladder with samples tested from the two phase 3 studies and the open-label extension study, neutralizing antibodies were developed in 0 of 954 patients (0.0%) while receiving unit doses of BOTOX 100 and in 3 of 260 patients (1.2%) after subsequently receiving at least a dose of 150 units. In patients with cervical dystonia whose safety was evaluated in open-label, double-blind studies after BOTOX injection, the most commonly reported adverse reactions were dysphagia (19%), upper respiratory tract infection (12%), neck pain (11%) and headache (11%).In the double-blind, placebo-controlled efficacy trials of chronic migraine (Study 1 and Study), the discontinuation rate was 12% in the group treated with BOTOX and 10% in the group treated with placebo.
Study 4 (NCT0115381) included 170 adult patients (87 with BOTOX and 83 with placebo) with upper limb spasticity that had passed at least 6 months since the stroke. The dosage in the initial and sequential treatment sessions should be adapted to each person depending on the size, number and location of the affected muscles, the severity of the spasticity, the presence of local muscle weakness, the patient's response to previous treatment, or the history of adverse effects related to Botox. It is not known if BOTOX and BOTOX Cosmetic are safe and effective in preventing headaches in people with migraines who have 14 or fewer headache days per month. (episodic migraine).
Ultimately, the choice between Botox and Dysport may depend on personal preferences and the specific needs of the treatment area. The safety and efficacy of BOTOX have been demonstrated by adequate and well-controlled studies on the use of BOTOX in patients aged 2 to 17 years with spasticity in the upper and lower extremities. Depending on where they are administered, cosmetic side effects of Botox injections include drooping and swelling of the eyelids. With a very fine needle, BOTOX Cosmetic is injected directly into the facial muscles that cause furrows and lines.
For example, Xeomin has been shown to effectively treat dynamic wrinkles as well as cervical dystonia, while Botox has a well-established track record of reducing facial wrinkles such as brow lines, crow's feet and neck bands, and has been shown to be an effective treatment for excessive sweating.
